Literature DB >> 2185538

Dopaminergic mechanisms in idiopathic and drug-induced psychoses.

J A Lieberman1, B J Kinon, A D Loebel.   

Abstract

Stimulant drugs such as cocaine and amphetamine are among the most commonly abused substances by schizophrenic patients. This may be due in part to aspects of the illness and treatment side effects that impel patients to use dopamine agonist drugs. Dopaminergic neural systems have been shown to mediate both stimulant drug effects and schizophrenia. Because of the hypothesized overlap in the pathophysiology of schizophrenia and the neurobiological effects of chronic stimulant use, the potential for serious complication of the primary disease by substance abuse exists. This article reviews the neurobiological mechanisms of behavioral sensitization and neurotoxicity associated with chronic stimulant administration in the context of pathophysiological theories of schizophrenia. Discussion focuses on the potential impact of stimulant use on the disease process as well as the manifest phenomenology and course of schizophrenia.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2185538     DOI: 10.1093/schbul/16.1.97

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  46 in total

Review 1.  Animal models of schizophrenia: a critical review.

Authors:  E R Marcotte; D M Pearson; L K Srivastava
Journal:  J Psychiatry Neurosci       Date:  2001-11       Impact factor: 6.186

Review 2.  Apomorphine and the dopamine hypothesis of schizophrenia: a dilemma?

Authors:  L Dépatie; S Lal
Journal:  J Psychiatry Neurosci       Date:  2001-05       Impact factor: 6.186

3.  Motivational responses to natural and drug rewards in rats with neonatal ventral hippocampal lesions: an animal model of dual diagnosis schizophrenia.

Authors:  R Andrew Chambers; David W Self
Journal:  Neuropsychopharmacology       Date:  2002-12       Impact factor: 7.853

4.  Striatal presynaptic dopamine in schizophrenia, Part I: meta-analysis of dopamine active transporter (DAT) density.

Authors:  Paolo Fusar-Poli; Andreas Meyer-Lindenberg
Journal:  Schizophr Bull       Date:  2012-01-26       Impact factor: 9.306

5.  Effects of a selective Y2R antagonist, JNJ-31020028, on nicotine abstinence-related social anxiety-like behavior, neuropeptide Y and corticotropin releasing factor mRNA levels in the novelty-seeking phenotype.

Authors:  Cigdem Aydin; Ozge Oztan; Ceylan Isgor
Journal:  Behav Brain Res       Date:  2011-04-08       Impact factor: 3.332

6.  Sigma1 receptor antagonists determine the behavioral pattern of the methamphetamine-induced stereotypy in mice.

Authors:  J Kitanaka; N Kitanaka; T Tatsuta; F S Hall; G R Uhl; K Tanaka; N Nishiyama; Y Morita; M Takemura
Journal:  Psychopharmacology (Berl)       Date:  2008-12-04       Impact factor: 4.530

Review 7.  Schizophrenia, "Just the Facts" 6. Moving ahead with the schizophrenia concept: from the elephant to the mouse.

Authors:  Matcheri S Keshavan; Henry A Nasrallah; Rajiv Tandon
Journal:  Schizophr Res       Date:  2011-02-12       Impact factor: 4.939

Review 8.  Synapsin III: role in neuronal plasticity and disease.

Authors:  Barbara Porton; William C Wetsel; Hung-Teh Kao
Journal:  Semin Cell Dev Biol       Date:  2011-07-30       Impact factor: 7.727

Review 9.  Acute and long-term effects of MDMA on cerebral dopamine biochemistry and function.

Authors:  M Isabel Colado; Esther O'Shea; A Richard Green
Journal:  Psychopharmacology (Berl)       Date:  2004-04-09       Impact factor: 4.530

Review 10.  Neurodegenerative aspects in vulnerability to schizophrenia spectrum disorders.

Authors:  Trevor Archer; Serafino Ricci; Danilo Garcia; Max Rapp Ricciardi
Journal:  Neurotox Res       Date:  2014-05-08       Impact factor: 3.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.